방사선산업학회지 (Journal of Radiation Industry)

한국방사선산업학회 (Korean Society of Radiation Industry)
권호 표지

ERCP 검사 시 방사선 피폭량과 암 위험도 분석

Analysis of Radiation Exposure and Cancer Risk of Patients during Therapeutic ERCP

  • 이양섭 (서울아산병원 영상의학과) ;
  • 서대건 (서울아산병원 영상의학과) ;
  • 조재환 (안산대학교 방사선과)
  • Lee, Yang-Sub (Department of Radiology, Asan Medical Center) ;
  • Suh, Dae-Keon (Department of Radiology, Asan Medical Center) ;
  • Cho, Jae-Hwan (Department of Radiological Technology, Ansan University)
  • 투고 : 2018.07.07
  • 심사 : 2018.08.27
  • 발행 : 2018.09.30

⟨ 이전 논문 다음 논문 ⟩

초록

Therapeutic endoscopic retrograde cholangiopancreatography (ERCP) requires fluoroscopic and radiographic exposures, which impose radiation risks to patients. The aim of the study was to calculate radiation doses for patients and cancer risk for patients during procedures by department. In this study, a total of 288 patients (Male: 182, female: 106), conducted using a ERCP system from January to March of 2016, were analyzed. A total of 288 patients were eligible, regardless of gender, with an average age of $61.28{\pm}13.4$ (19~91) years. The procedures were performed in the radiology department using a fluoroscopy X-ray machine (multidiagnost ELEVA FD). In study, fluoroscopy time, DAP (Dose area product) values, effective dose and cancer risk by department were measured. DAP measurements can be used to estimate an effective dose (ED) and cancer risk to patients undergoing ERCP. Mean fluoroscopy time of all departments was $7.05{\pm}7min$ (0.4~71.2 min). LTS (liver transplantation & hepatobiliary surgery) had the highest fluoroscopy time with $10.58{\pm}7.93min$, and HBP (hepatobiliary pancreatic surgery) had the lowest fluoroscopy time with $3.38{\pm}1.93min$ (p<0.01). Mean DAP values of all departments was $8.40{\pm}7.77mGy{\cdot}cm^2$. LTS had the highest DAP value with $11.96{\pm}9.03mGy{\cdot}cm^2$, and HBP had the lowest DAP value with $4.15{\pm}2.73mGy{\cdot}cm^2$ (p<0.01). Mean effective dose of all departments was $0.68{\pm}0.63mSv$. LTS had the highest effective dose with $0.97{\pm}0.73mSv$, and HBP had the lowest effective dose with $0.34{\pm}0.22mSv$ (p<0.01). Mean cancer risk of all departments was $1.007{\pm}0.006$ time, and LTS had the highest cancer risk with 1.06 time (p<0.01). LTS had the highest cancer risk with 1.06 time but the risk is low in the approximate 1.0 times. Therapeutic ERCP procedure is beneficial to the patient, but may be necessary comprehensive management and efforts to reduce radiation dose.

키워드

참고문헌

  1. Boix J and Lorenzo-Zuniga V. 2011. Radiation dose to patients during endoscopic retrograde cholangiopancreatography. World J. Gastrointest Endosc. 3(7):140-144. https://doi.org/10.4253/wjge.v3.i7.140
  2. Dumonceau JM, Garcia-Fernandez FJ and Verdun FR. 2012. Radiation protection in digestive endoscopy: European Society of Digestive Endoscopy (ESGE) guideline. Endoscopy. 44(4):408-421. https://doi.org/10.1055/s-0031-1291791
  3. Griffey RT and Sodickson A. 2009. Cumulative radiation exposure and cancer risk estimates in emergency department patients undergoing repeat or multiple CT. AJR Am. J. Roentgenol. 192(4):887-892. https://doi.org/10.2214/AJR.08.1351
  4. Huda W, Ogden KM and Khorasani MR. 2008. Converting dose-length product to effective dose at CT. Radiology. 248(3):995-1003. https://doi.org/10.1148/radiol.2483071964
  5. ICRP. 1990. Recommendations of the International Commission on Radiological Protection.
  6. ICRP. 2007. The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103. Stockholm, Sweden: ICRP.
  7. International Agency for Research on Cancer. 2000. IARC monographs on the evaluation of carcinogenic risks to humans. Ionizing radiation: part 1. X- and gamma-radiation and neutrons. Lyon: International Agency for Research on Cancer.
  8. Kang DH. 2003. ERCP for Diagnosis and Therapy: The NIH State-of-the-Science Conference. Korean J Pancreas Biliary Tract. 8(1):1-8.
  9. Kim JH, Park Chan, Song JH, Kim YT, Yim NY, Chang NK, Kim JK and Kang HK. 2013. Cumulative Radiation Exposures during Diagnosis and Treatments with Diagnostic Radiology Tools: In Patient with Hepatocellular Carcinoma. J. Korean Soc. Radiol. 69(3):243-250. https://doi.org/10.3348/jksr.2013.69.3.243
  10. Kim YJ, Cho KB, Kim ES, Park KS, Jang BK, Chung WJ and Hwang JS. 2011. Efficacy of a self-designed protective lead shield in reduction of radiation exposure dose during endoscopic retrograde cholangiopancreatography. Korean J. Gastroenterol. 57(1):28-33. https://doi.org/10.4166/kjg.2011.57.1.28
  11. Lee SY, Lim HS and Han MS. 2011. The Evaluation of patients' radiation dose during TACE of interventional radiology. J. Radiol. Sci. Technol. 34(1):209-214.
  12. Lee W. 2011. Current status of medical radiation exposure and regulation efforts. J. Korean Med Association. 54(1):1248-1252.
  13. Marcos A. 2000. Right-lobe living donor liver transplantation. Liver Transpl. 6(l):59-63.
  14. Mettler FA, Bhargavan M, Faulkner K, Gilley DB, Gray JE, Ibbott GS, Lipoti JA, Mahesh M, McCrohan JL, Stabin MG, Thomadsen BR, Yoshizumi TT. 2009. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources-1950-2007. Radiology. 253(2):520-531. https://doi.org/10.1148/radiol.2532082010
  15. Monique T. Barakat,a Nirav C. Thosani,a Robert J. Huang, Abhishek Choudhary, Rajan Kochar, Shivangi Kothari, and Subhas Banerjee. 2018. Effects of a Brief Educational Program on Optimization of Fluoroscopy to Minimize Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography. Clinical Gastroenterology and Hepatology. 16:550-557.
  16. Moser MA and Wall WJ. 2001. Management of biliary problems after liver transplantation. Liver Transpl. 7(l):46-52.
  17. National Research Council (US). 2006. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington DC: National Academies Press.
  18. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K and Kodama K. 2007. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat. Res. 168(1):1-64.
  19. Rodriguez-Perlavarez ML, Minano-Herrrero JA, Hervas-Molina AJ, Benitez-Cantero JM, Garcia-Sanchez V, Naranjo-Rodriguez A, Pleguezuelo-Navarro M, Soler-Cantos Mdel M and de la Mata-Garcia M. 2011. Radio induced cancer risk during ERCP. Is it a real clinical problem?. Rev. Esp. Enferm. Dig. 103(4):191-195. https://doi.org/10.4321/S1130-01082011000400004
  20. Shim CS. 2006. Recent Progress in Biliopancreatic Therapeutic Endoscopy. Korean J Pancreas Biliary Tract. 11(1):29-43.
  21. Son BK, Lee KT, Kim JS and Lee SO. 2011. Lack of radiation protection for endoscopists performing endoscopic retrograde cholangiopancreatography. Korean J. Gastroenterol. 58(2):93-99. https://doi.org/10.4166/kjg.2011.58.2.93
  22. Stecker MS, Balter S, Towbin RB, Miller DL, Vano E, Bartal G, Angle JF, Chao CP, Cohen AM, Dixon RG, Gross K, Hartnell GG, Schueler B, Statler JD, de Baere T and Cardella JF. 2009. Guidelines for patient radiation dose management. J. Vasc. Interv Radiol. 20(1):263-273.
  23. Sung DW. 2001. Radiation exposure in diagnostic areas: issues and countermeasures. J. Korean Med. Assoc. 54(12):1246-1247. https://doi.org/10.5124/jkma.2011.54.12.1246
  24. Tsapaki V, Paraskeva KD, Mathou N, Andrikopoulos E, Tentas P, Triantopoulou C and Karagiannis JA. 2011. Patient and endoscopist radiation doses during ERCP procedures. Radiat. Prot. Dosimetry. 147(1-2): 111-113. https://doi.org/10.1093/rpd/ncr285
  25. Valentin J. 2000. Avoidance of radiation injuries from medical interventional procedures. Ann ICRP. 30(2):7-67. https://doi.org/10.1016/S0146-6453(01)00004-5
  26. Valentin J. 2005. Low-dose extrapolation of radiation-related cancer risk. Ann ICRP. 35(4):1-140. https://doi.org/10.1016/j.icrp.2005.11.002